business newsMyrexis and Gilead Sciences Among Most Active Stocks in Nasdaq Pre-Market
By
Christopher Witrak
Nov 12, 2012 9:25 am
Clovis Oncology was down this morning.
PRINT
-
Stay Connected
-
-
-
-
MINYANVILLE ORIGINAL The three most active funds and stocks in pre-market trading on the Nasdaq (INDEXNASDAQ:.IXIC) were Myrexis (NASDAQ:MYRX), Gilead Sciences (NASDAQ:GILD), and Clovis Oncology (NASDAQ:CLVS) as of 9:15 a.m. EST.
Investors traded 2,098,200 shares of Myrexis, which was up $0.42, or 17.95%. Reuters reported today that the board of directors of Myrexis have decided to dissolve the biopharmaceutical company. Shareholders will receive approximately between $72.9 million and $77.9 million, or between $2.72 and $2.91 per share.
Investors exchanged 1,435,288 shares of Gilead Sciences, which was up $7.47, or 11.49%. According to Bloomberg, a combination of Gilead's experimental hepatitis C therapies removed the virus in 100% of patients in trial.
Investors also traded 563,272 shares of Clovis Oncology, which was down $8.74, or 40.67%. Clovis' experimental drug for pancreatic cancer, CP-4126, failed in a late stage trial. The company has suspended all development of the drug.
Twitter: @ChrisWitrak
Investors traded 2,098,200 shares of Myrexis, which was up $0.42, or 17.95%. Reuters reported today that the board of directors of Myrexis have decided to dissolve the biopharmaceutical company. Shareholders will receive approximately between $72.9 million and $77.9 million, or between $2.72 and $2.91 per share.
Investors exchanged 1,435,288 shares of Gilead Sciences, which was up $7.47, or 11.49%. According to Bloomberg, a combination of Gilead's experimental hepatitis C therapies removed the virus in 100% of patients in trial.
Investors also traded 563,272 shares of Clovis Oncology, which was down $8.74, or 40.67%. Clovis' experimental drug for pancreatic cancer, CP-4126, failed in a late stage trial. The company has suspended all development of the drug.
Twitter: @ChrisWitrak
No positions in stocks mentioned.
Daily Recap
Everything you need to know for the next trading day.
Trading Radar (weekly)
Your road map to all the events that will effect financial markets in the week ahead.
Name
Email
*
Phone
* required field
